Table 2.
Best overall response (ITT population)
| Best overall response | Pembrolizumab N = 30 |
Chemotherapy N = 22 |
||
|---|---|---|---|---|
| n | % (95% CI)a | n | % (95% CI)a | |
| Objective response rate (CR + PR) | 6 | 20.0 (7.7–38.6) | 4 | 18.2 (5.2–40.3) |
| CR | 3 | 10.0 (2.1–26.5) | 1 | 4.5 (0.1–22.8) |
| PR | 3 | 10.0 (2.1–26.5) | 3 | 13.6 (2.9–34.9) |
| SD | 2 | 6.7 (0.8–22.1) | 10 | 45.5 (24.4–67.8) |
| Disease control rate (CR + PR + SD) | 8 | 26.7 (12.3–45.9) | 14 | 63.6 (40.7–82.8) |
| Progressive disease | 20 | 66.7 (47.2–82.7) | 3 | 13.6 (2.9–34.9) |
| No assessment | 0 | 6.7 (0.8–22.1) | 3 | 9.1 (1.1–29.2) |
| Nonevaluable | 2 | 0.0 (0.0–11.6) | 2 | 13.6 (2.9–34.9) |
CI confidence interval, CR complete response, ITT intention-to-treat, PR partial response, SD stable disease
aBased on binomial exact CI method